| Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study MC Tammemagi, H Schmidt, S Martel, A McWilliams, JR Goffin, ... The lancet oncology 18 (11), 1523-1531, 2017 | 204 | 2017 |
| The cost-effectiveness of high-risk lung cancer screening and drivers of program efficiency S Cressman, SJ Peacock, MC Tammemägi, WK Evans, NB Leighl, ... Journal of Thoracic Oncology 12 (8), 1210-1222, 2017 | 139 | 2017 |
| USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study MC Tammemägi, M Ruparel, A Tremblay, R Myers, J Mayo, J Yee, ... The Lancet Oncology 23 (1), 138-148, 2022 | 94 | 2022 |
| Conducting clinical trials—costs, impacts, and the value of clinical trials networks: a scoping review C Bentley, S Cressman, K van der Hoek, K Arts, J Dancey, S Peacock Clinical Trials 16 (2), 183-193, 2019 | 74 | 2019 |
| Binding and Uptake of RGD-Containing Ligands to Cellular α v β 3 Integrins S Cressman, Y Sun, EJ Maxwell, N Fang, DDY Chen, PR Cullis International Journal of Peptide Research and Therapeutics 15, 49-59, 2009 | 55 | 2009 |
| A time-trend economic analysis of cancer drug trials S Cressman, GP Browman, JS Hoch, L Kovacic, SJ Peacock The oncologist 20 (7), 729-736, 2015 | 51 | 2015 |
| Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada S Cressman, S Lam, MC Tammemagi, WK Evans, NB Leighl, DA Regier, ... Journal of thoracic oncology 9 (10), 1449-1458, 2014 | 50 | 2014 |
| Synthesis of a labeled RGD− lipid, its incorporation into liposomal nanoparticles, and their trafficking in cultured endothelial Cells S Cressman, I Dobson, JB Lee, YYC Tam, PR Cullis Bioconjugate chemistry 20 (7), 1404-1411, 2009 | 50 | 2009 |
| Health-related quality of life and anxiety in the PAN-CAN lung cancer screening cohort N Taghizadeh, A Tremblay, S Cressman, S Peacock, AM McWilliams, ... BMJ open 9 (1), e024719, 2019 | 34 | 2019 |
| Capillary Electrophoresis Frontal Analysis for Characterization of αvβ3 Integrin Binding Interactions Y Sun, S Cressman, N Fang, PR Cullis, DDY Chen Analytical chemistry 80 (9), 3105-3111, 2008 | 34 | 2008 |
| Economic impact of genomic diagnostics for intermediate‐risk acute myeloid leukaemia S Cressman, A Karsan, DE Hogge, E McPherson, C Bolbocean, ... British journal of haematology 174 (4), 526-535, 2016 | 13 | 2016 |
| Pan-Canadian Early Detection of Lung Cancer Study Team. Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada S Cressman, S Lam, MC Tammemagi, WK Evans, NB Leighl, DA Regier, ... J Thorac Oncol 9 (10), 1449-58, 2014 | 11 | 2014 |
| Cost-effectiveness of pharmacogenomic-guided treatment for major depression S Ghanbarian, GWK Wong, M Bunka, L Edwards, S Cressman, T Conte, ... CMAJ 195 (44), E1499-E1508, 2023 | 10 | 2023 |
| Applying utility values in cost-effectiveness analyses of lung cancer screening: a review of methods PJ Ngo, S Cressman, S Behar-Harpaz, DJ Karikios, K Canfell, MF Weber Lung Cancer 166, 122-131, 2022 | 10 | 2022 |
| ILST (International Lung Screening Trial) investigator consortium. protocol and rationale for the international lung screening trial KP Lim, H Marshall, M Tammemägi, F Brims, A McWilliams, E Stone, ... Ann Am Thorac Soc 17 (4), 503-512, 2020 | 9 | 2020 |
| Economic impact of using risk models for eligibility selection to the International lung screening Trial S Cressman, MF Weber, PJ Ngo, S Wade, SB Harpaz, M Caruana, ... Lung Cancer 176, 38-45, 2023 | 6 | 2023 |
| Updated cost-effectiveness analysis of lung cancer screening for Australia, capturing differences in the health economic impact of NELSON and NLST outcomes S Behar Harpaz, MF Weber, S Wade, PJ Ngo, P Vaneckova, PEA Sarich, ... British Journal of Cancer 128 (1), 91-101, 2023 | 5 | 2023 |
| Health utilities for participants in a population-based sample who meet eligibility criteria for lung cancer screening PJ Ngo, S Wade, P Vaneckova, SB Harpaz, M Caruana, S Cressman, ... Lung Cancer 169, 47-54, 2022 | 5 | 2022 |
| Economic evidence for the use of risk-selection and risk-stratification for lung cancer screening programs S Cressman, S Lam, M Tammemaegi, S Peacock JOURNAL OF THORACIC ONCOLOGY 10 (9), S192-S192, 2015 | 4 | 2015 |
| Fifty-year forecasts of daily smoking prevalence: can Australia reach 5% by 2030? S Wade, MF Weber, P Sarich, M Caruana, C Watts, P Vaneckova, P Ngo, ... Tobacco Control, 2023 | 3 | 2023 |
